Clinical evaluation of the role of ceftaroline in the management of community acquired bacterial pneumonia

ical evaluation of the role of ceftaroline in the management of community acquired bacterial pneumonia Review (3096) Total Article Views Authors: Maselli DJ, Fernandez JF, Whong CY, Echevarria K, Nambiar AM, Anzueto A, Restrepo MI Published Date February 2012 Volume 2012:5 Pages 43 - 51 DOI: http://dx.doi.org/10.2147/IDR.S17433 Received: 02 November 2011 Accepted: 28 December 2011 Published: 01 February 2012 Diego J Maselli1, Juan F Fernandez1, Christine Y Whong2, Kelly Echevarria1,3, Anoop M Nambiar1,3, Antonio Anzueto1,3, Marcos I Restrepo1,3,4 1University of Texas Health Science Center, San Antonio, Texas, 2Memorial Hermann – Texas Medical Center, Houston, TX, 3South Texas Veterans Health Care System Audie l Murphy Division, San Antonio, TX, 4Veterans Evidence Research Dissemination and Implementation Center (VERDICT), San Antonio, TX, USA Abstract: Ceftaroline fosamil (ceftaroline) was recently approved for the treatment of community-acquired pneumonia (CAP) and complicated skin infections. This newly developed cephalosporin possesses a broad spectrum of activity against gram-positive and gram-negative bacteria. Most importantly, ceftaroline demonstrates potent in vitro antimicrobial activity against multi-drug resistant Streptococcus pneumoniae and methicillin-resistant strains of Staphylococcus aureus. In two Phase III, double-blinded, randomized, prospective trials (FOCUS 1 and FOCUS 2), ceftaroline was shown to be non-inferior to ceftriaxone for the treatment of CAP in hospitalized patients. Ceftaroline exhibits low resistance rates and a safety profile similar to that of other cephalosporins. In this review, we will evaluate the pharmacological characteristics, safety, antimicrobial properties, and efficacy of ceftaroline and its applications in the treatment of CAP.